Hepatotoxic Effects of Lipid-Altering Agents

被引：0
|
作者：
Korth, Christine E. [1 ]
Backes, James M. [2 ,3 ]
机构：
[1] Nebraska Med Ctr, Omaha, NE 68198 USA
[2] Univ Kansas, Med Ctr, Sch Pharm & Med, Pharm Practice, Kansas City, KS 66103 USA
[3] Univ Kansas, Med Ctr, Atherosclerosis & LDL Apheresis Ctr, Kansas City, KS 66103 USA
来源：
US PHARMACIST | 2012年 / 37卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：HS17 / HS20
页数：4
相关论文
共 50 条
  • [21] Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk
    Farnier, Michel
    CURRENT CARDIOLOGY REPORTS, 2016, 18 (07)
  • [22] Model-based development of gemcabene, a new lipid-altering agent
    Jaap W. Mandema
    David Hermann
    Wenping Wang
    Tim Sheiner
    Mark Milad
    Rebecca Bakker-Arkema
    Daniel Hartman
    The AAPS Journal, 7
  • [23] Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk
    Michel Farnier
    Current Cardiology Reports, 2016, 18
  • [24] Model-based development of gemcabene, a new lipid-altering agent
    Mandema, JW
    Hermann, D
    Wang, WP
    Sheiner, T
    Milad, M
    Bakker-Arkema, R
    Hartman, D
    AAPS JOURNAL, 2005, 7 (03): : E513 - E522
  • [25] Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?
    Hochholzer, Willibald
    Giugliano, Robert P.
    CURRENT ATHEROSCLEROSIS REPORTS, 2013, 15 (01)
  • [26] Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?
    Willibald Hochholzer
    Robert P. Giugliano
    Current Atherosclerosis Reports, 2013, 15
  • [27] Anti-inflammatory effect is an important property of niacin on atherosclerosis beyond its lipid-altering effects
    Yu, Bi-lian
    Zhao, Shui-ping
    MEDICAL HYPOTHESES, 2007, 69 (01) : 90 - 94
  • [28] Lipid-altering drugs: Decreasing cardiovascular disease at the expense of increasing cancer?
    Goldstein, MR
    CANCER RESEARCH, 2004, 64 (18) : 6831 - 6831
  • [29] Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies
    Robert S Rosenson
    Bertram Pitt
    Nature Clinical Practice Cardiovascular Medicine, 2009, 6 : 98 - 100
  • [30] Antioxidant versus lipid-altering therapy - Some answers, more questions
    Freedman, JE
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (22): : 1636 - 1637
12345